These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
170 related items for PubMed ID: 17243195
1. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Jones RW, Bayer A, Inglis F, Barker A, Phul R. Int J Geriatr Psychiatry; 2007 Mar; 22(3):258-62. PubMed ID: 17243195 [Abstract] [Full Text] [Related]
2. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Farlow MR, Alva G, Meng X, Olin JT. Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593 [Abstract] [Full Text] [Related]
3. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. Schulz JB, Rainer M, Klünemann HH, Kurz A, Wolf S, Sternberg K, Tennigkeit F. J Alzheimers Dis; 2011 Feb; 25(3):463-75. PubMed ID: 21471647 [Abstract] [Full Text] [Related]
4. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. Ott BR, Blake LM, Kagan E, Resnick M, Memantine MEM-MD-11AB Study Group. J Neurol; 2007 Mar; 254(3):351-8. PubMed ID: 17345042 [Abstract] [Full Text] [Related]
5. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, Gauthier S. Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915 [Abstract] [Full Text] [Related]
6. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy. Sakka P, Tsolaki M, Hort J, Hager K, Soininen H, López Pousa S, Li C, Schwam E. Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434 [Abstract] [Full Text] [Related]
7. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Wilkinson D, Andersen HF. Dement Geriatr Cogn Disord; 2007 Dec; 24(2):138-45. PubMed ID: 17622761 [Abstract] [Full Text] [Related]
8. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Arch Neurol; 2006 Jan; 63(1):49-54. PubMed ID: 16401736 [Abstract] [Full Text] [Related]
9. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Periclou A, Ventura D, Rao N, Abramowitz W. Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248 [Abstract] [Full Text] [Related]
10. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Dement Geriatr Cogn Disord; 2012 Jan; 33(2-3):164-73. PubMed ID: 22572767 [Abstract] [Full Text] [Related]
11. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Pomara N, Ott BR, Peskind E, Resnick EM. Alzheimer Dis Assoc Disord; 2007 Jan; 21(1):60-4. PubMed ID: 17334274 [Abstract] [Full Text] [Related]
12. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Bassil N, Thaipisuttikul P, Grossberg GT. Expert Opin Pharmacother; 2010 Jul; 11(10):1765-71. PubMed ID: 20540654 [Abstract] [Full Text] [Related]
13. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Gauthier S, Wirth Y, Möbius HJ. Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444 [Abstract] [Full Text] [Related]
14. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date. Bullock R. Alzheimer Dis Assoc Disord; 2006 May; 20(1):23-9. PubMed ID: 16493232 [Abstract] [Full Text] [Related]
15. Memantine (Ebixa) in clinical practice - results of an observational study. Calabrese P, Essner U, Forstl H. Dement Geriatr Cogn Disord; 2007 May; 24(2):111-7. PubMed ID: 17622714 [Abstract] [Full Text] [Related]
16. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Kisicki JC, Fiske K, Lyne A. Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196 [Abstract] [Full Text] [Related]
17. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. Waldemar G, Hyvärinen M, Josiassen MK, Kørner A, Lehto H, Wetterberg P. Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874 [No Abstract] [Full Text] [Related]
18. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I. Dement Geriatr Cogn Disord; 2007 Sep; 23(5):301-6. PubMed ID: 17356273 [Abstract] [Full Text] [Related]
19. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Dement Geriatr Cogn Disord; 2007 Sep; 24(1):20-7. PubMed ID: 17496417 [Abstract] [Full Text] [Related]
20. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Gauthier S, Loft H, Cummings J. Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838 [Abstract] [Full Text] [Related] Page: [Next] [New Search]